Loading...
OTCMPBIO
Market cap93kUSD
Dec 23, Last price  
0.00USD
1D
0.00%
1Q
-91.07%
Jan 2017
-99.96%
Name

Pressure Biosciences Inc

Chart & Performance

D1W1MN
OTCM:PBIO chart
P/E
—
P/S
0.05
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
72.43%
Rev. gr., 5y
-4.25%
Revenues
2m
+14.36%
412,616105,526210,289645,870852,2631,244,9101,340,032987,7291,238,2171,503,2881,374,7441,797,6911,976,4872,240,4982,457,8711,809,9931,220,5912,002,3651,729,3431,977,763
Net income
-29m
L+74.24%
12,712,585872,974-2,413,111-1,155,661-4,908,445-2,568,316-3,128,262-2,996,312-3,450,205-4,084,427-4,612,540-7,415,298-2,706,984-10,715,561-9,699,318-11,660,917-24,349,779-34,603,727-16,824,351-29,314,298
CFO
-3m
L-28.85%
-1,836,817-2,828,260-2,113,942-4,114,482-4,420,209-1,809,261-2,872,180-2,141,863-2,164,801-2,342,603-3,210,578-3,819,746-3,805,851-3,904,549-5,695,904-6,327,578-4,883,194-4,868,573-4,478,041-3,186,010
Earnings
Jun 05, 2025

Profile

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.
URL
https://www.pressurebiosciences.com/
IPO date
Oct 31, 1996
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,978
14.36%
1,729
-13.63%
2,002
64.05%
Cost of revenue
11,481
6,628
6,188
Unusual Expense (Income)
NOPBT
(9,503)
(4,898)
(4,185)
NOPBT Margin
Operating Taxes
748
14,450
Tax Rate
NOPAT
(9,503)
(5,646)
(18,635)
Net income
(29,314)
74.24%
(16,824)
-51.38%
(34,604)
42.11%
Dividends
(386,300)
(184,274)
Dividend yield
2,687.14%
1,202.02%
Proceeds from repurchase of equity
231
25
184,274
BB yield
-3.00%
-0.17%
-1,202.02%
Debt
Debt current
22,663
20,240
14,230
Long-term debt
351
572
808
Deferred revenue
5
2
4
Other long-term liabilities
(150)
(150)
Net debt
22,871
20,744
14,845
Cash flow
Cash from operating activities
(3,186)
(4,478)
(4,869)
CAPEX
(7)
(21)
(123)
Cash from investing activities
(7)
(21)
(123)
Cash from financing activities
3,271
4,370
5,105
FCF
(12,114)
(1,137)
(18,918)
Balance
Cash
81
4
132
Long term investments
62
64
60
Excess cash
44
92
Stockholders' equity
(132,991)
(101,693)
(86,470)
Invested Capital
123,127
89,388
78,757
ROIC
ROCE
96.35%
40.30%
55.34%
EV
Common stock shares outstanding
23,337
11,058
6,637
Price
0.33
-74.62%
1.30
-43.72%
2.31
8.96%
Market cap
7,701
-46.43%
14,376
-6.23%
15,330
118.85%
EV
30,572
35,121
30,177
EBITDA
(9,391)
(4,779)
(4,075)
EV/EBITDA
Interest
15,581
10,439
14,450
Interest/NOPBT